Swiss pharma major Novartis AG on Monday lost a seven-year long legal battle for getting its blood cancer drug Glivec patented in India and to restrain Indian companies from manufacturing generic drugs, with the Supreme Court rejecting the multinational company's plea.
For more content go to [ Ссылка ]
Follow us on facebook at [ Ссылка ]
Follow us on twitter at [ Ссылка ]
